TMCnet News
Spotlight Innovation Backs Promising Glaucoma Treatment with Strategic Investment in Solx, Inc.SANTA MONICA, CA, Dec. 5, 2016 /CNW/ - Online Media Group Covers Spotlight Innovation (OTCQB: STLT) Spotlight Innovation, Inc. recently announced that it has made a strategic investment in Solx, Inc., a Massachusetts-based, privately held medical device company. Principally backed by MVM Life Science Partners, LLP, a leading global life science venture capital firm, Solx develops innovative surgical technologies that treat glaucoma, the second leading cause of blindness in the world. Spotlight Innovation identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging, and neglected diseases. With its investment in Solx, Spotlight Innovation recognizes a unique opportunity to improve the lives of patients suffering from refractory glaucoma. Solx's lead product is the SOLX Gold Shunt™, a first-in-class, implantable drainage device designed to safely reduce elevated intraocular pressure (IOP) asociated with refractory glaucoma without creating a bleb, a common source of complications associated with the current therapies. The device provides a pathway for the flow of aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye. The SOLX Gold Shunt is approved for use in Canada and Europe. It has been tested in a multicenter clinical trial and is investigational and awaiting FDA approval in the U.S. In addition to its external investment in Solx, Spotlight Innovation has an internal development pipeline that includes product candidates for cancer, chronic pain, Zika virus infection, and spinal muscular atrophy (SMA). To learn more about Spotlight Innovation, interested parties are encouraged to visit the Company's website at: http://www.spotlightinnovation.com. Legal Disclaimer: Online Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Financial Press Media Group, Inc. may have received compensation from the companies mentioned in this release. SOURCE Online Media Group Inc 
|